Turoctocog alfa - Novo Nordisk

Drug Profile

Turoctocog alfa - Novo Nordisk

Alternative Names: N8; NN-7008; NNC-0155-0000-0004; NovoEight; Recombinant factor VIII - Novo Nordisk; rFVIII - Novo Nordisk; Zonovate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 20 Jun 2017 Novo Nordisk completes the phase I guardian ™9 trial in Haemophilia A in USA, Bulgaria, Germany, Taiwan, Austria, Serbia and Spain (NCT02941354)
  • 14 Mar 2017 Phase-III clinical trials in Haemophilia A (In children, In adults, In adolescents, Treatment-experienced) in Austria (SC) (EudraCT2016-003821-40)
  • 30 Jan 2017 Phase-I clinical trials in Haemophilia A (In children, In the elderly, In adolescents, In adults) in USA and Germany (SC) (NCT02994407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top